Nevada
|
000-53401
|
98-0588402
|
||
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
c/o
Yantai Bohai Pharmaceuticals Group Co. Ltd.
No.
9 Daxin Road, Zhifu District
Yantai,
Shandong Province, China 264000
|
(Address
of principal executive offices)
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
Item 1.01
|
Entry
into a Material Definitive
Agreement.
|
Number
|
Name
of the Medicines
|
DANs
|
1
|
Yinqiao
Detoxification Pellet
|
Z37020715
|
2
|
Tianwang
heart nourishing Pellet
|
Z37020714
|
3
|
Tongxuan
lung Pellet
|
Z37020717
|
4
|
Ruyi
Jinhuang Powder
|
Z37020709
|
5
|
Xiaohuoluo
Pellet
|
Z37020711
|
6
|
Dieda
Pellet
|
Z37020723
|
7
|
Qipi
Pellet
|
Z37020685
|
8
|
Ginseng
Guipi Pellet
|
Z37020716
|
9
|
Spleen
Pellet
|
Z37020712
|
10
|
Jiufen
Powder
|
Z37020683
|
11
|
Wu
Zi Yan Zong Pellet
|
Z37020707
|
12
|
Qingwen
Detoxification Pellet
|
Z37020708
|
13
|
Wuhu
Powder
|
Z37020710
|
14
|
Hawthorn
Pellet
|
Z37020713
|
|
10.1
|
Unofficial
English Translation of the Intangible Assets Transfer Agreement, dated
December 9, 2010, by and between the Company and Shandong Daxin
Microbiology Pharmaceutical Industry Co.,
Ltd.
|
|
99.1
|
Press
Release, dated December 14, 2010, regarding the Company’s agreement with
Shandong Daxin Microbiology Pharmaceutical Industry Co.,
Ltd.
|
Bohai
Pharmaceuticals Group, Inc.
|
|||
December
14, 2010
|
By:
|
/s/ Gene Hsiao | |
Name: Gene Hsiao | |||
Title: Chief Financial Officer | |||